From: Current trials for frontline therapy of mantle cell lymphoma
BTK inhibitor | Ibrutinib |
Acalabrutinib | |
Bgb-3111 | |
Anti-CD20 | Rituximab |
Obinutuzumab | |
Ofatumumab | |
Tositumomab | |
Anti-B1 antibody | |
Ibritumomab | |
Alkylating agent | Bendamustine |
Immuno-modulator | Thalidomide |
Lenalidomide | |
Purine analog | Cladribine |
Proteasome inhibitor | Bortezomib |
mTOR inhibitor | Temsirolimus |
Radioisotope | Iodine 131I Tositumomab |
131I Anti-B1 antibody | |
90Y-Ibritumomab tiuxetan |